Furthermore, treatment guidelines (e.g., [14,15]) tend to recommend sequential single-agent regimens for HER2-negative disease, with combination chemotherapy being used for select cases, including patients with high tumor burden, rapid disease progression, or visceral crisis. Here, ERBB2 is linked to neoplasm.